Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm Clinical Trial

Official title:

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03426254
• Other study ID #: TST-9-H
• Status: Withdrawn
• Phase: Phase 1
• Start date: November 10, 2022
• Est. completion date: January 10, 2024

Study information

• Verified date: March 2023
• Source: Center Trials & Treatment
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Description:

The intent of this study was to assess the safety and efficacy of two forms of Talazoparib therapy for the treatment of advanced solid tumors . After an enrollment period, patients will randomized to receive oral Talazoparib (1 mg, one times a day ) or subcutaneously Talazoparib (1 mg by subcutaneous injection with NovoPen / Autopen) one times a day in the appropriate volume

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 10, 2024
• Est. primary completion date: December 10, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.

• Female of at least 21 years of age.

• Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator

• Eastern Cooperative Oncology Group (ECOG) Performance status (PS) = 2.

• Renal function at screening and enrollment as defined by the

• Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.

• Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.

• Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.

• Received at least 1 and no more than 3 platinum-based chemotherapy regimens (prior bevacizumab is allowed) and the last dose is = 28 days before randomization

• No prior PARP inhibitor treatment

• Adequate other organ function at screening and enrollment.

• Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 60 days after the last dose of study drug.

• Female patients must not be breastfeeding at screening nor during the study participation until 60 days after the last dose of study drug.

• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion Criteria:

• Terminology Criteria for Adverse Events [CTCAE] grade = 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.

• Use of any investigational agent within 14 days before randomization.

• Had > 2 paracentesis procedures within 28 days before randomization.

• Major surgery within 14 days before randomization.

• Requirement for intravenous alimentation (at the time of randomization).

• Seropositive for human immunodeficiency virus (HIV).

• Any serious or unstable medical condition that interferes with ability to tolerate treatment or assessments associated with the protocol.

• Gastrointestinal disorder affecting absorption.

• Known or suspected hypersensitivity to any of the talazoparib capsule components.

• Any condition or reason that interferes with ability to participate in the study, tolerate treatment or assessments associated with the protocol, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator or Medical Monitor.

Related Conditions & MeSH terms

• Advanced or Recurrent Solid Tumors
• Breast Neoplasm
• Breast Neoplasms

Intervention

Biological:
• Injections Subcutaneously Talazoparib
Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28

Drug:
• Oral capsules Talazoparib
Patients receive 1 mg of Talazoparib PO QD on days 1-28.

Locations

Country	Name	City	State
Albania	University -Mother Theresa- Hospital, Oncology Dep.	Tirana

Sponsors (2)

Lead Sponsor	Collaborator
Center Trials & Treatment	BioGene Pharmaceutical

Country where clinical trial is conducted

Albania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib ( 1 mg / dose )	Frequency of occurrence and evaluation of adverse events in the use of Subcutaneously Talazoparib , assessed by percentage of patients with any Adverse Event (AE), leading to Study Drug Discontinuation, Serious Adverse Event (SAE), related to study drug, SAE related to study drug.; Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03 Incidence of toxicity, graded according to the National Cancer Institute (NCI) CTCAE version 4.03	Anticipated in about 12 month following first patient enrolled
Secondary	Clinical Benefit of Injections Subcutaneously Talazoparib	Clinical benefit (CB) defined as any of the following, complete response, partial response, or stable disease for > 24 weeks by RECIST 1.1. Assessments performed using computed tomography (CT) or magnetic resonance imaging (MRI) or ultrasound examination (Use) scan every 9 weeks.	Every 9 weeks for 12 months